Coronavirus Vaccine Injury Compensation: Why mRNA, Viral Vector & Other Platforms Differ in Liability Claims (Key Differences Explained)

As South Korea expands its compensation framework for COVID-19 vaccine-related injuries, questions persist about how different vaccine platforms—mRNA versus viral vector—are evaluated under the new rules. The government’s Ministry of Health and Welfare (MoHW) has clarified that distinctions in compensation eligibility stem from scientific differences in how each platform triggers immune responses. While the updated Special Act on Vaccine Injury Compensation broadens coverage, critics argue the system remains inconsistent and places undue burden on victims to prove causality.

Under the revised legislation, which took effect on October 23, 2025, 13 previously “supported” conditions—including Guillain-Barré syndrome—are now fully compensable under the national scheme. However, the MoHW emphasizes that compensation is not automatic: each case must undergo medical review to confirm whether symptoms are directly linked to vaccination. This requirement has drawn scrutiny, particularly as global health agencies like the World Health Organization (WHO) and the U.S. National Academy of Medicine (NAM) classify vaccine-related adverse events differently by platform.

For example, the viral vector vaccines (AstraZeneca, Johnson & Johnson/Janssen) have been statistically associated with Guillain-Barré syndrome in post-marketing studies, whereas mRNA vaccines (Pfizer-BioNTech, Moderna) have not shown the same correlation. Yet under South Korea’s system, compensation for Guillain-Barré syndrome remains tied to the vaccine type administered—a distinction that frustrates patients who develop identical symptoms regardless of which vaccine they received.

Why the Platform Divide Matters

Vaccine platforms operate through fundamentally different mechanisms:

• mRNA vaccines deliver genetic instructions (mRNA) to cells, prompting them to produce the spike protein that triggers an immune response. Side effects, when they occur, tend to be mild (e.g., fever, fatigue) and short-lived.
• Viral vector vaccines use a harmless virus (e.g., adenovirus) as a delivery system for genetic material. This method can provoke stronger immune reactions, including rare but serious events like blood clots or neurological complications.

Global regulators, including the European Medicines Agency (EMA), have documented these platform-specific risks. Yet South Korea’s compensation framework treats them as separate categories—even when a patient’s symptoms match known profiles for multiple platforms. “It’s illogical,” said one patient advocate in a Hankyung newspaper interview. “If I get the same illness after vaccination, I shouldn’t be penalized for which vaccine I happened to receive.”

How the New Rules Work (and Where They Fall Short)

The 2025 amendments represent a significant shift in South Korea’s approach to vaccine safety. Previously, only 13 conditions were eligible for compensation; now, the MoHW evaluates claims on a case-by-case basis, provided the injury meets scientific criteria for vaccine-relatedness. However, the burden of proof remains with the patient:

“Not all post-vaccination symptoms are vaccine-related. We must ensure compensation targets only those with clear causal links.”
—MoHW spokesperson, as reported by Korea.net

Critics argue this process is unfairly onerous. For instance, a patient who develops Guillain-Barré syndrome after receiving an mRNA vaccine—despite no proven link—would likely be denied compensation, while an identical case after a viral vector vaccine might qualify. The MoHW defends the system, citing the need to prevent fraudulent claims, but patient groups say the rules disproportionately disadvantage those who cannot afford private legal representation.

Global Context: How Other Countries Handle Vaccine Compensation

South Korea’s approach contrasts with systems in the U.S. And EU, where compensation is often presumed for listed adverse events, regardless of vaccine type. The U.S. Vaccine Injury Table includes Guillain-Barré syndrome as compensable after any COVID-19 vaccine, while the EU’s pharmacovigilance system treats all vaccines equally under its passive surveillance model. Japan, meanwhile, operates a no-fault compensation scheme that covers all vaccine-related injuries without platform distinctions.

In South Korea, the debate hinges on risk perception versus scientific evidence. While viral vector vaccines carry documented risks for rare events like Guillain-Barré syndrome, mRNA vaccines have not been linked to the same complications—yet patients who experience identical symptoms after mRNA vaccination face an uphill battle to prove their case. “The science is clear,” said Dr. Lee Ji-hoon, a professor of infectious diseases at Seoul National University. “But compensation policies must balance public trust with fiscal responsibility.”

What’s Next: Key Developments to Watch

The MoHW has pledged to review the compensation framework annually, with the next assessment due by October 2026. Patient advocacy groups are pushing for:

• A platform-neutral evaluation process for rare adverse events.
• Expanded access to legal aid for claimants.
• Transparency in how global studies (e.g., WHO/NAM reports) are incorporated into local rulings.

For now, victims of suspected vaccine-related injuries are advised to:

• Document symptoms and medical records immediately after vaccination.
• Submit claims through the MoHW’s online portal within 6 months of symptom onset.
• Seek support from organizations like the Korean Vaccine Injury Association for guidance.

Key Takeaways

• The 2025 amendments broaden but do not eliminate platform-based distinctions in compensation.
• Guillain-Barré syndrome remains compensable only after viral vector vaccines, despite no proven link to mRNA vaccines.
• Patients bear the burden of proving causality, a process critics call unfair and medically inconsistent.
• Global regulators (WHO, EMA) classify risks by platform, but South Korea’s system treats them as separate legal categories.
• The next policy review is scheduled for October 2026.

As South Korea navigates the post-pandemic era, the vaccine compensation debate reflects broader tensions between scientific precision and public equity. For now, patients and advocates urge the MoHW to align its rules with international standards—where compensation focuses on injury, not the vaccine that caused it.

Have you or a loved one experienced a suspected vaccine-related injury? Share your story in the comments or contact the MoHW’s vaccine safety hotline for guidance. For updates on the 2026 policy review, bookmark this page.